- Global Pharma News & Resources

Daiichi Sankyo Announces the Presentation of New Data on LIXIANA®▼ (edoxaban) to be Presented at ESC Congress 2019

  • Data presentations from ENTRUST-AF PCI and ETNA-AF add to the growing body of scientific evidence from the Edoxaban Clinical Research Programme
  • First-time presentation of ENTRUST-AF PCI clincial results assessing edoxaban in atrial fibrillation (AF) patients following a successful percutaneous coronary intervention
  • Presentations from ETNA-AF programme on real-world use of edoxaban in regional and European-specific clinical practice include one year follow-up of more than 12,500 AF patients in Europe

Munich, Germany (22 August 2019) – Daiichi Sankyo Europe GmbH (hereafter, Daiichi Sankyo) today announced clinical results for edoxaban (known by the brand name LIXIANA®▼) will be featured as a late-breaking oral presentation and as poster presentations at ESC Congress 2019, taking place from 31 August-04 September in Paris, France.

Clinical results from the ENTRUST-AF PCI study will be presented during a late-breaking science session at the congress. It is the first study to evaluate edoxaban in atrial fibrillation (AF) patients following a successful stent placement for acute coronary syndrome or stable coronary artery disease. ENTRUST-AF PCI was a multicentre, prospective, randomised, open-label, blinded-endpoint evaluation trial performed at 186 sites in 18 countries.1

In addition, five analyses from the global ETNA-AF programme describing the real-world use of oral, once-daily edoxaban in regional and European-specific routine clinical practice will be featured in poster sessions. These analyses will provide important clinical insights in patients with nonvalvular AF, including elderly patients, those with extremely low and high body weight, those with low-, intermediate- and high-risk for stroke and bleeding, and those with history of intracranial haemorrhage. The programme is comprised of more than 20,000 patients in Europe, East Asia and Japan followed for two years and nearly 14,000 patients from 10 European countries followed for four years.2-7

As part of the Edoxaban Clinical Research Programme, these studies add to the growing evidence of edoxaban use in a broad range of cardiovascular conditions, patient types and clinical settings.

Details of the edoxaban-related presentations are as follows:

Presentation Title


Session Details

Late-Breaking Oral Presentation

Edoxaban-Based Versus Vitamin-K-Antagonist-Based Anti-Thrombotic Regimen Following Successful Coronary Stenting in Atrial Fibrillation Patients. The ENTRUST-AF PCI Trial

Andreas Goette, MD

St. Vincenz-Hospital, Paderborn, Germany

Tuesday, 03 September 2019

Paris – Main Auditorium


Poster Presentations



ETNA-AF Europe: First 1-Year Follow-Up Snapshot Analysis of More Than 7,500 AF Patients Treated With Edoxaban in Routine Clinical Practice

Raffaele De Caterina, MD

University of Pisa, Pisa, Italy


Sunday, 01 September 2019

Moderated ePoster 7 – Poster Area


Clinical Characteristics and 1-Year Outcomes in Atrial Fibrillation Patients With or Without History of Intracranial

Haemorrhage Treated With Edoxaban: Snapshot Analysis of the Global ETNA-AF Program

Paulus Kirchhof, MD

University of Birmingham, School of Clinical and Experimental Medicine,

Birmingham, United Kingdom

Monday, 02 September 2019

Posters – Poster Area


One-Year Outcomes of Elderly Patients with Atrial Fbrillation: Snapshot Data from the Global Noninterventional

Program on Edoxaban Treatment in Routine Clinical Practice in Atrial Fibrillation

Chun-Chieh Wang, MD

Chang Gung University, Department of Cardiology, Taipei, Taiwan ROC

Monday, 02 September 2019

Posters – Poster Area


Edoxaban Treatment in Routine Clinical Practice for Patients with Atrial Fibrillation (AF) in Europe (ETNA-AF-Europe): 1-Year Follow-Up According to Body Mass Index

Thomas Weiss, MD

Karl Landsteiner Institute for Cardiometabolics and SFU, Vienna, Austria

Monday, 02 September 2019

Posters – Poster Area


Stroke and Bleeding in Low, Intermediate and High Risk Patients With Atrial Fibrillation Treated With Edoxaban: Results of the ETNA-AF Europe Registry

Joris R. de Groot, MD

University of Amsterdam,  Amsterdam, Netherlands

Monday, 02 September 2019

Posters – Poster Area




































EdoxabaN TReatment VersUS Vitamin K Antagonist in PaTients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention (ENTRUST-AF- PCI) is a prospective, multinational, multicenter, randomised, open-label with blinded endpoint evaluation phase 3b study. The ENTRUST-AF PCI trial was designed to evaluate the safety and accrue exploratory information on the efficacy of an edoxaban-based antithrombotic regimen compared to a VKA-based antithrombotic regimen in patients with AF following successful PCI with stent implantation. The primary objective of the ENTRUST-AF PCI trial was to compare the incidence of major or clinically relevant non-major International Society on Thrombosis and Haemostasis (ISTH)-defined bleeding over a 12-month period of an edoxaban-based antithrombotic regimen against a VKA-based regimen. 1,506 patients were enrolled in ENTRUST-AF PCI from 186 clinical sites across Europe and Asia. Participants were randomly allocated in a 1:1 ratio to a 12-month antithrombotic regimen of edoxaban and a P2Y12 inhibitor or to a standard therapy with a vitamin K antagonist (VKA) and P2Y12 inhibitor plus acetyl salicylic acid for one to 12 months.1

About ETNA-AF 

ETNA-AF (Edoxaban Treatment in routiNe clinical prActice in patients with nonvalvular Atrial Fibrillation) is a global programme that combines data from distinct non-interventional studies in Europe, East Asia, and Japan in a single database. A total of more than 28,000 patients will be included in the ETNA-AF registries and followed for two years (patients in Europe will be followed for four years). The primary objective of ETNA-AF is to collect information on the use of edoxaban in routine clinical practice, including the safety and efficacy profile in non-preselected patients with non-valvular atrial fibrillation (NVAF).2-7

About Atrial Fibrillation

AF is a condition where the heart beats irregularly and rapidly. When this happens, blood can pool and thicken in the chambers of the heart causing an increased risk of blood clots. These blood clots can break off and travel through the blood stream to the brain (or sometimes to another part of the body), where they have the potential to cause a stroke.8

AF is the most common type of heart rhythm disorder, and is associated with substantial morbidity and mortality.9 More than six million Europeans are diagnosed with AF, and this figure is expected to at least double over the next 50 years.10,11 Compared to those without AF, people with the arrhythmia have a 3-5 times higher risk of stroke.12 One in five of all strokes are a result of AF.10

About Edoxaban

Edoxaban is an oral, once-daily, direct factor Xa (pronounced “Ten A”) inhibitor. Factor Xa is one of the key components responsible for blood clotting, so inhibiting this makes the blood thin and less prone to clotting. Edoxaban is currently marketed by Daiichi Sankyo and its partners in more than 30 countries and regions around the world.

About the Edoxaban Clinical Research Programme

More than 10 studies, more than 100,000 patients worldwide

Daiichi Sankyo is committed to expanding scientific knowledge about edoxaban, as demonstrated through research programmes evaluating its use in a broad range of cardiovascular conditions, patient types and clinical settings in atrial fibrillation (AF) and venous thromboembolism (VTE) designed to further build on the results of the pivotal ENGAGE-AF and Hokusai-VTE studies. More than 100,000 patients worldwide are expected to participate in the Edoxaban Clinical Research Programme, which is comprised of more than 10 RCTs (randomised, controlled trials), registries and non-randomised clinical studies, including completed, ongoing and future research. Our goal is to generate new edoxaban clinical and real-world-data regarding its use in AF and VTE populations, providing physicians and patients worldwide with greater treatment assurance.

The RCTs include:

  • ENGAGE AF-TIMI 48 (Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation), in AF patients at moderate-to-high risk of thromboembolic events
  • Hokusai VTE (Edoxaban in Venous Thromboembolism), in patients with either acute symptomatic deep vein thrombosis (DVT), pulmonary embolism (PE) or both
  • ENSURE-AF (EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation), in AF patients undergoing electrical cardioversion
  • ENTRUST-AF PCI (EdoxabaN TReatment versUS VKA in paTients with AF undergoing PCI), in AF patients undergoing percutaneous coronary intervention
  • Hokusai-VTE Cancer (Edoxaban in Venous Thromboembolism Associated with Cancer), in patients with cancer and an acute VTE event
  • ELDERCARE-AF (Edoxaban Low-Dose for EldeR CARE AF patients), in elderly AF patients in Japan
  • ELIMINATE-AF (EvaLuatIon of edoxaban coMpared with VKA IN subjects undergoing cAThEter ablation of non-valvular Atrial Fibrillation)
  • ENVISAGE-TAVI AF (EdoxabaN Versus standard of care and theIr effectS on clinical outcomes in pAtients havinG undergonE Transcatheter Aortic Valve Implantation (TAVI) – Atrial Fibrillation)
  • STABLED Study (STroke secondary prevention with catheter ABLation and EDoxaban for patients with non-valvular atrial fibrillation) in Japan
  • ENRICH-AF (EdoxabaN foR IntraCranial Hemorrhage survivors with Atrial Fibrillation, an investigator initiated phase III study)

In addition, global and regional registry and non-randomised clinical studies provide important real-world and clinical data about the use of edoxaban and other oral anticoagulants in everyday practice; these include:

  • ETNA-AF (Edoxaban Treatment in routiNe clinical prActice in patients with nonvalvular Atrial Fibrillation)
  • ETNA-VTE (Edoxaban Treatment in routiNe clinical prActice in patients with Venous ThromboEmbolism)
  • EMIT-AF/VTE (Edoxaban Management In diagnostic and Therapeutic procedures-AF/VTE)
  • Prolongation PREFER in AF (PREvention oF thromboembolic events – European Registry) in patients with AF
  • ANAFIE (All Nippon AF In Elderly) Registry in Japan
  • Cancer-VTE Registry in Japan
  • RYOUMA (Real world ablation therapY with anti-cOagUlants in Management of Atrial fibrillation) Registry in Japan
  • KYU-RABLE (Multicenter study associated with KYU-shu to evaluate the efficacy and safety of edoxaban in patients with non-valvulaR Atrial fiBriLlation undergoing cathEter ablation) in Japan
  • BPV-AF (Atrial Fibrillation with BioProsthetic valve) Registry in Japan

Through the Edoxaban Clinical Research Programme, we are committed to adding to the scientific body of knowledge around edoxaban in a variety of AF and VTE patients, including those who are vulnerable.

About Daiichi Sankyo

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets. With over 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for hypertension and thrombotic disorders, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo research and development is primarily focused on bringing forth novel therapies in oncology, including immuno-oncology, with additional focus on new horizon areas, such as pain management, neurodegenerative diseases, heart and kidney diseases, and other rare diseases. For more information, please visit:

Editor Details

  • Company:
    • Daiichi Sankyo Europe GmbH
  • Name:
    • Daiichi Sankyo Europe GmbH
Last Updated: 22-Aug-2019